NCT00295646 2024-03-15
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
Austrian Breast & Colorectal Cancer Study Group
Phase 3 Completed
Clinical Trials
37 trialsNCT00556374 2023-07-27
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Amgen
Phase 3 Completed
NCT00321464 2022-11-08
A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.
Amgen
Phase 3 Completed
NCT01345019 2022-11-08
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
Amgen
Phase 3 Completed
NCT00330759 2022-11-07
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.
Amgen
Phase 3 Completed
NCT00127205 2021-07-02
S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.
SWOG Cancer Research Network
Phase 3 Completed
NCT00079001 2020-05-12
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT01099436 2020-01-21
NEO-ZOTAC
Borstkanker Onderzoek Groep
Phase 3 Completed
NCT00987636 2019-10-22
EWING2008
University Hospital Muenster
Phase 3 Completed
NCT00869206 2018-11-07
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00321620 2018-08-29
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer
Amgen
Phase 3 Completed
NCT00329797 2017-11-29
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00193856 2017-10-12
RADAR Trial - Randomised Androgen Deprivation and Radiotherapy
Trans Tasman Radiation Oncology Group
Phase 3 Completed
NCT00086268 2017-09-13
ZPACT
Novartis
Phase 3 Completed
NCT00375648 2017-06-02
TRAPEZE
Novartis
Phase 3 Completed
NCT00172055 2017-03-06
Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy
Novartis
Phase 3 Completed
NCT00171639 2017-02-23
The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis
Novartis
Phase 3 Completed
NCT01920568 2017-01-16
A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors
GlaxoSmithKline
Phase 3 Completed
NCT00107263 2016-12-06
Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00022087 2016-07-19
Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00685646 2015-10-16
ZAPCA
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase 3 Completed
NCT00172042 2015-05-04
A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)
Novartis
Phase 3 Completed
NCT00512993 2015-03-05
NATAN
GBG Forschungs GmbH
Phase 3 Completed
NCT00320710 2014-08-22
Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer
Novartis
Phase 3 Completed
NCT00242567 2014-05-07
Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer
Novartis
Phase 3 Completed
NCT00712985 2014-04-24
CTIBL
Milton S. Hershey Medical Center
Phase 3 Completed
NCT00033332 2014-04-04
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00049452 2014-01-06
Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00352846 2013-07-02
Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00003884 2013-02-21
Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
Novartis
Phase 3 Completed
NCT00432458 2012-07-04
Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma
Mayo Clinic
Phase 3 Completed
NCT00171340 2012-04-16
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.
Novartis
Phase 3 Completed
NCT00171314 2012-04-11
The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer
Novartis
Phase 3 Completed
NCT00375427 2012-04-11
Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions
Novartis
Phase 3 Completed
NCT00332709 2011-11-16
Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
Novartis
Phase 3 Completed
NCT00376740 2011-08-23
Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole
Soroka University Medical Center
Phase 3 Completed
NCT00219258 2009-11-23
Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma
Novartis
Phase 3 Completed